MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action Lawsuit - Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

Core Viewpoint - A securities class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][4]. Company Allegations - The lawsuit centers on claims that MoonLake misled investors regarding the superiority of its Nanobody technology compared to conventional monoclonal antibodies, particularly against the FDA-approved competitor BIMZELX [3]. - The specific event that triggered the stock drop was the failure of the VELA-2 trial to meet its primary endpoint, revealing that the drug's efficacy was inferior to that of its competitor [4]. Financial Impact - MoonLake's stock price plummeted from $61.99 to $6.24, representing a 90% loss on September 29, 2025, after the trial results were announced [4]. Investor Guidance - Investors who purchased MoonLake stock between March 10, 2024, and September 29, 2025, and experienced significant losses are encouraged to contact Hagens Berman to explore their legal options and potential appointment as Lead Plaintiff [5].